Facilitated angioplasty: Neither black nor white;Angioplastia facilitada: Ni blanco ni negro

Revista Espanola de Cardiologia

Volumn 58, Issue 2, 2005, Pages 111-118

  Sánchez, Pedro L ^a   Fernández Avilés, Francisco ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; TICLOPIDINE;

ANGIOPLASTY; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY STENT; DRUG EFFICACY; EDITORIAL; FIBRINOLYTIC THERAPY; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; MORTALITY; PROGNOSIS; REVASCULARIZATION; ST SEGMENT ELEVATION; THROMBOGENESIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 15944389471     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13071883     Document Type: Editorial

References (41)

1. Arós F. Loma-Osorio A, Bosch X, Gonzaáles Aracil J, López Bescós L, Marrugat J, et al. Manejo del infarto de miocardio en España (1995-1999). Datos del registro de infartos de la Sección de Cardiopatía Isquémica y Unidades Coronarias (RISCI) de la Sociedad Española de Cardiología. Rev Esp Cardiol. 2001;54: 1033-40.
2. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction and improved survival: should the paradigm be expanded? Circulation. 1989;79:441-4.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003:361: 13-20.
4. Hasdai D, Behar S, Vallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survery of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002;23:1190-201.
5. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J; GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359:373-7.
6. Gibson CM. NRMI and current treatment patterns for ST-elevation myocardial infarction. Am Heart J. 2004;148:S29-33.
7. Yusuf S, Collins R, Peto R, Furberg C, Stamfer MJ, Goldhaber SZ, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985;6:556-85.
8. Boersma E, Mass ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction. Reappraisal of the golden hour. Lancet. 1996;348:771-5.
9. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-82.
10. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med. 1993;329:1615-22.
11. Ohnam EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, et al. Consequences of reocclusion after succesful reperfusion therapy in acute myocardial infarction: the TAMI Study Group. Circulation. 1990;82:781-91.
12. Granger CB, White HD, bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol. 1994:74:1220-8.
13. Keeley EC, Cigarroa JE. Facilitated primary percutaneous transluminal coronary angioplasty for acute ST segment elevation myocardial infarction: rationale for reuniting pharmacologic and mechanical revascularization strategies. Cardiol Rev. 2003;11:13-20.
14. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. BMJ. 1991;302:555-60.
15. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med. 1989;320:618-27.
16. Barbash GI, Roth A, Hod H, Modan M, Miller HI, Rath S, et al. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:538-45.
17. Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42:634-41.
18. Fernández-Avilés F, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso-Briales J, et al; GRACIA (Grupo de Análisis de la Cardiopatía Isquémica Aguda) Group. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA 1): a randomised controlled trial. Lancet. 2004;364:1045-53.
19. Sánchez PL, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso J, et al. Grupo de Análisis de la Cardiopatía Isquémica Aguda (GRACIA). Resultados del estudio GRACIA 1 (comparación en el IAM entre revascularización en las 24 horas tras trombólisis y el tratamiento conservador) en la población anciana. Rev Esp Cardiol. 2004;57 Supl 2:120.
20. Alonso JJ, Sánchez PL, Castro A, López J, Calvo I, Martínez L, et al. Grupo de Análisis de la Cardiopatía Isquémica Aguda (GRACIA). Resultados del estudio GRACIA 1 (comparación en el IAM entre revascularización en las 24 horas tras trombólisis y el tratamiento conservador) en la población diabética. Rev Esp Cardiol. 2004;57 Supl 2:135.
21. Montalescot G, Barragan P, Wittenberg O, Escollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-903.
22. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stent following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-21.
23. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879-85.
24. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346:957-66.
25. Lee DP, Herity NA, Hiatt BL, Fearon BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation. 2003;107:1497-501.
26. Van't Hof AWJ, Ernst N, DeBoer MJ, De Winter R, Boersma E, Bunt T, et al. Facilitation of primary coronary angioplasty by early start a glycoprotein 2b/3a inhibitor: results of the On-going Tirofiban in Myocardial Infarction Evaluation (On-TIME) trial. Eur Heart J. 2004;25:837-46.
27. Cutlip DE, Ricciardi MJ, Frederick SL, Fearon WF, Rezaee M, Carter AJ, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol. 2003;92:977-80.
28. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2002;90:533-6.
29. Arntz HR, Schroder JF, Pels K, Schwimmbeck P, Witzenbichler B, Schultheiss HP, et al. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study [abstract]. Eur Heart J. 2003;24 Suppl:268.
30. Mesquita Gabriel H, Oliveira J, Canas da Silva P, Marques da Costa J, Correia da Cunha JA, França C, et al. Early administration of abciximab bolus in the emergency room improves micro-perfusion after primary percutaneous coronary intervention, as assessed by TIMI frame count: results of the ERAMI trial [abstract]. Eur Heart J. 2003;24 Suppl:543.
31. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1886-9.
32. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004; 292:362-6.
33. Liem A, Zijlstra F, Ottervanger JP, Hoorntje JC, Suryapranata H, De Boer MJ, et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol. 2000;35:600-4.
34. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol. 1999;34:1954-62.
35. Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, et al. Facilitation or early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction. Results from SPEED (GUSTO 4 Pilot) Trial. J Am Coll Cardiol. 2000;36:1489-96.
36. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J. 2000;21:823-31.
37. Fernández-Avilés F, Alonso JJ, Castro Beiras A, Goicolea J, Blanco J, Alonso J, et al. Primary optimal PCI versus facilitated intervention (Tenecteplase plus stenting) in patients with ST elevated acute myocardial infarction: the GRACIA 2 randomized trial [abstract]. Circulation. 2003;108 Suppl:2149.
38. Antman EM. Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis: result of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 investigators. Circulation 1999;99:2720-32.
39. Brener SJ, Zeymer U, Adgey AA, Vrobel TR, Ellis SG, Neuhaus KL, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol. 2002;39:377-86.
40. Giugliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol. 2003;16:1251-60.
41. Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, et al. Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004;291:947-54.